In our new era of precision medicine, physicians, researchers and regulatory agencies are exploring new ways to advance the drug development process. This has already led to significant progress and successful examples for clinical trial innovation are especially prominent in Oncology. Several novel study designs have recently proven their value also for rare disease subtypes and have been accepted by regulatory authorities. In addition, the access to novel types of data allows treatment advances to be matched to specific patients and potentially reach them earlier. This talk addresses the relevance of learning from Oncology clinical trial innovation for chronic inflammatory conditions.